Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
CheckMate 9DW at ASCO GI 2026: Nivolumab plus ipilimumab vs lenvatinib ...
CheckMate 9DW Breakthrough: Nivolumab and Ipilimumab Show Promise as ...
CheckMate 9DW Study Results and Use of Ipiimumab/Nivolumab in First ...
Extended Follow-Up Data From CheckMate 9DW Supports Nivo/Ipi as 1L ...
CheckMate 9DW Expanded Analyses: Nivo/Ipi Versus Len/Sor as 1L Therapy ...
CheckMate 9DW: nivolumab and ipilimumab outcomes by IMAEs in HCC ...
CheckMate 9DW: Ipi/Nivo as First-Line Treatment for uHCC - YouTube
孙惠川教授：CheckMate 9DW 研究扩展分析结果重磅发布，O+Y 方案再证长生存获益丨2025 ASCO GI_腾讯新闻
Neue Erstlinientherapie bei inoperablem Leberzellkarzinom: CheckMate ...
CheckMate 8HW Trial at ASCO 2025: Nivolumab Plus Ipilimumab Sets New ...
CheckMate 9DW: the future of checkpoint inhibitors in advanced HCC ...
ESMO 2021: CheckMate 9KD Cohort A2 Final Analysis: Nivolumab ...
FDA Approves Nivolumab and Ipilimumab for First-Line Treatment of ...
Angela Lamarca: Update form CHECKMATE-9DW trial in HCC - Asian ...
eCase - Tx of Advanced HCC | CCO
CheckMate-9DW: First-Line Nivolumab/Ipilimumab Prolongs Overall ...
Advancing First-Line Therapy for Unresectable Hepatocellular Carcinoma ...
Nivolumab plus ipilimumab vs. Lenvatinib or sorafebib as first-line ...
FDA Approves Nivolumab and Ipilimumab as First-Line Treatment for ...
First-Line Nivolumab Plus Ipilimumab Could Become New Standard Care for ...
First-Line Nivolumab/Ipilimumab Improves Survival in Unresectable ...
CheckMate-9DW trial evaluating Opdivo (nivolumab) + Yervoy (ipilimumab ...
An Introduction to Front-line Nivolumab/Ipilimumab Therapy for uHCC ...
First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus ...
First-line nivolumab plus ipilimumab combined with two cycles of ...
DailyMed - OPDIVO QVANTIG- nivolumab and hyaluronidase-nvhy injection ...
【ASCO 2024】洞察诊疗前沿，看晚期HCC免疫联合治疗新进展-MedSci.cn
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line ...
FDA OKs Nivolumab/Ipilimumab in Unresectable/Metastatic HCC
盛锡楠教授：转移性肾癌BIONIKK、CheckMate 9ER研究——免疫和靶向，并排走还是前后走丨瞭望FM·ESMO特辑_治疗
Nivolumab Plus Ipilimumab Improves OS and Response in Frontline uHCC
LBA 4008 Annual Meeting of the American Society of Clinical Oncology ...
2025 ESMO GI|秦叔逵教授：CheckMate-9DW中国人群扩展分析揭晓，O+Y以循证力量驱动中国HCC一线治疗变革医药新闻 ...
Nivolumab plus ipilimumab combination therapy in patients with advanced ...
Opdivo (Nivolumab Injection): Side Effects, Uses, Dosage, Interactions ...
OPDIVO® (nivolumab) + YERVOY® (ipilimumab) in the first-line treatment ...
Efficacy Data Support Nivolumab/Ipilimumab as First-Line HCC Treatment
Out in the lancet! 👉Nivolumab plus ipilimumab vs lenvatinib or ...
FDA Approves Nivolumab/Ipilimumab in First-Line Hepatocellular Cancer
Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib ...
ASCO GU 2023: Nivolumab plus Cabozantinib vs Sunitinib for First-Line ...
ASCO GU 2021: Patient-Reported Outcomes Of Patients With Advanced Renal ...
Breakthroughs in Hepatocellular Carcinoma Therapies - Clinical ...
First-line nivolumab plus ipilimumab with two cycles of chemotherapy ...
Nivolumab plus Ipilimumab versus Lenvatinib or Sorafenib as First-Line ...
Frontiers | Nivolumab adjuvant therapy for esophageal cancer: a review ...
CheckMate-9DW研究：O+Y一线治疗晚期肝细胞癌 - 知乎
(PDF) First-Line Nivolumab Plus Ipilimumab With Chemotherapy for ...
BMS’s Checkmate-9DW Trial Shows Opdivo Plus Yervoy Efficacy in Advanced ...
FDA Approves Nivolumab With Ipilimumab for First-Line Treatment of ...
ESMO Virtual Congress 2020: First Results From the Randomized Phase 3 ...
30641-0/asset/58152fdc-1b05-44e3-8d75-6c64df3d642f/main.assets/gr1.gif)